TY - JOUR
T1 - Impact of non-gated computed tomography on the timing of invasive strategy of patients with non-ST-elevation acute coronary syndrome
AU - Miyagawa, Masatsugu
AU - Arai, Riku
AU - Takahashi, Kurara
AU - Nakajima, Yuki
AU - Migita, Shohei
AU - Mizobuchi, Saki
AU - Tanaka, Yudai
AU - Fukumoto, Katsunori
AU - Morikawa, Tomoyuki
AU - Mineki, Takashi
AU - Kojima, Keisuke
AU - Murata, Nobuhiro
AU - Sudo, Mitsumasa
AU - Okumura, Yasuo
N1 - Publisher Copyright:
2023 Miyagawa, Arai, Takahashi, Nakajima, Migita, Mizobuchi, Tanaka, Fukumoto, Morikawa, Mineki, Kojima, Murata, Sudo and Okumura.
PY - 2023
Y1 - 2023
N2 - Background: This study aimed to examine the clinical role of non-gated computed tomography (CT) in ruling out fatal chest pain in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), with a focus on the time of arrival at the hospital to coronary angiography (CAG) and peak creatine kinase (CK) levels. Methods: We retrospectively examined 196 NSTE-ACS patients who were admitted with urgently diagnosed NSTE-ACS and underwent percutaneous coronary intervention between March 2019 and October 2022. The patients were divided into three groups, namely, non-CT group, CT and defect− group, and CT and defect+ group, based on whether they underwent a CT scan and the presence or absence of perfusion defects on the CT image. Results: After the initial admission for NSTE-ACS, 40 patients (20.4%) underwent non-gated CT prior to CAG. Among these 40 patients, 27 had a perfusion defect on the CT scan. The incidence of contrast-induced nephropathy was not different among the three groups. The CT and defect+ group had a shorter arrival-to-CAG time than that of the non-CT group. In NSTE-ACS patients with elevated CK levels, the CT and defect+ group had lower peak CK levels than those in the non-CT group. Conclusion: NSTE-ACS patients with perfusion defects on non-gated CT had a shorter time from arrival to CAG, which might be associated with a lower peak CK. Non-gated CT might be useful for early diagnosis and early revascularization in the clinical setting of NSTE-ACS.
AB - Background: This study aimed to examine the clinical role of non-gated computed tomography (CT) in ruling out fatal chest pain in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), with a focus on the time of arrival at the hospital to coronary angiography (CAG) and peak creatine kinase (CK) levels. Methods: We retrospectively examined 196 NSTE-ACS patients who were admitted with urgently diagnosed NSTE-ACS and underwent percutaneous coronary intervention between March 2019 and October 2022. The patients were divided into three groups, namely, non-CT group, CT and defect− group, and CT and defect+ group, based on whether they underwent a CT scan and the presence or absence of perfusion defects on the CT image. Results: After the initial admission for NSTE-ACS, 40 patients (20.4%) underwent non-gated CT prior to CAG. Among these 40 patients, 27 had a perfusion defect on the CT scan. The incidence of contrast-induced nephropathy was not different among the three groups. The CT and defect+ group had a shorter arrival-to-CAG time than that of the non-CT group. In NSTE-ACS patients with elevated CK levels, the CT and defect+ group had lower peak CK levels than those in the non-CT group. Conclusion: NSTE-ACS patients with perfusion defects on non-gated CT had a shorter time from arrival to CAG, which might be associated with a lower peak CK. Non-gated CT might be useful for early diagnosis and early revascularization in the clinical setting of NSTE-ACS.
KW - coronary angiography
KW - creatine kinase
KW - non-ST-elevation acute coronary syndrome (NSTE-ACS)
KW - non-ST-elevation myocardial infarction (NSTEMI)
KW - non-gated computed tomography
KW - perfusion defect
UR - http://www.scopus.com/inward/record.url?scp=85178471582&partnerID=8YFLogxK
U2 - 10.3389/fcvm.2023.1266767
DO - 10.3389/fcvm.2023.1266767
M3 - Article
AN - SCOPUS:85178471582
SN - 2297-055X
VL - 10
JO - Frontiers in Cardiovascular Medicine
JF - Frontiers in Cardiovascular Medicine
M1 - 1266767
ER -